UroGen Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) announces participation in two healthcare conferences: the H.C. Wainwright & Co. Global Investment Conference on May 25 at 11:00 a.m. ET and the Jefferies Healthcare Conference on June 9 at 1:00 p.m. ET. Webcasts for both events will be accessible on UroGen's website, with replays available for 30 days. UroGen focuses on developing innovative solutions for urothelial and specialty cancers, utilizing its proprietary RTGel™ technology for improved treatment options.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences:

H.C. Wainwright & Co. Global Investment Conference

• Wednesday, May 25 at 11:00 a.m. ET

Jefferies Healthcare Conference

• Thursday, June 9 at 1:00 p.m. ET

Webcasts of both the H.C. Wainwright & Co. and Jefferies presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005277/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

UroGen Corporate Communications

cindy.romano@urogen.com

908-963-7827

Source: UroGen Pharma Ltd.

FAQ

What conferences will UroGen Pharma attend in 2023?

UroGen Pharma will attend the H.C. Wainwright & Co. Global Investment Conference on May 25 and the Jefferies Healthcare Conference on June 9.

When is UroGen Pharma's presentation at the H.C. Wainwright conference?

UroGen Pharma's presentation at the H.C. Wainwright conference is scheduled for May 25 at 11:00 a.m. ET.

What time will UroGen Pharma present at the Jefferies Healthcare Conference?

UroGen Pharma will present at the Jefferies Healthcare Conference on June 9 at 1:00 p.m. ET.

Where can I watch UroGen Pharma's conference presentations?

UroGen Pharma's conference presentations can be watched via the Investors section on their website, with replays available for 30 days.

What is UroGen Pharma's focus in the healthcare market?

UroGen Pharma focuses on developing innovative solutions for treating urothelial and specialty cancers.